Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04287608 · ClinicalTrials.gov registry record
Observational Study of Conjunctivitis in the Setting of DUPIXENT® Treatment for Atopic Dermatitis
A clinical trial, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- 50
- Enrollment target
NCT04287608: Completed study, sponsored by Regeneron Pharmaceuticals.
NCT04287608 is a clinical trial that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04287608 has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- 50 participants
- Enrollment target
Study Summary
The primary objective of the study is to characterize the clinical phenotype(s) of DUPIXENT®-associated conjunctivitis events. The secondary objectives of the study are to characterize the course of conjunctivitis events during the observation period and collect and assess data on treatment for conjunctivitis events and its effectiveness.
Primary Outcome
Diagnosis includes: symptoms and morphological features of conjunctivitis
Interventions
- DRUG dupilumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2021-03-10 |
| Est. Completion | 2023-03-29 |
What the finished NCT04287608 record still lists
NCT04287608 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which dupilumab is the first listed.
NCT04287608 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04287608 about?
NCT04287608 is a clinical study titled "Observational Study of Conjunctivitis in the Setting of DUPIXENT® Treatment for Atopic Dermatitis". The primary objective of the study is to characterize the clinical phenotype(s) of DUPIXENT®-associated conjunctivitis events. The secondary objectives of the study are to characterize the course of conjunctivitis events during the observation period and collect and assess data on treatment for con...
What is the current status of trial NCT04287608?
This trial is currently completed. The enrollment target is 50 participants. The study started on 2021-03-10. Estimated completion is 2023-03-29.
What interventions are being tested in trial NCT04287608?
The interventions under investigation include: dupilumab (DRUG).
Who is sponsoring clinical trial NCT04287608?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI